Symbols / GDTC
GDTC Chart
About
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.20M |
| Enterprise Value | 9.71M | Income | -3.67M | Sales | 729.88K |
| Book/sh | 0.49 | Cash/sh | 0.25 | Dividend Yield | — |
| Payout | 0.00% | Employees | 43 | IPO | — |
| P/E | — | Forward P/E | -6.93 | PEG | — |
| P/S | 16.72 | P/B | 2.13 | P/C | — |
| EV/EBITDA | -3.05 | EV/Sales | 13.31 | Quick Ratio | 4.30 |
| Current Ratio | 5.81 | Debt/Eq | 6.78 | LT Debt/Eq | — |
| EPS (ttm) | -0.25 | EPS next Y | -0.15 | EPS Growth | — |
| Revenue Growth | 101.00% | Earnings | — | ROA | -22.85% |
| ROE | -42.33% | ROIC | — | Gross Margin | 92.52% |
| Oper. Margin | -4.52% | Profit Margin | 0.00% | Shs Outstand | 11.73M |
| Shs Float | 3.68M | Short Float | 0.41% | Short Ratio | 0.37 |
| Short Interest | — | 52W High | 3.68 | 52W Low | 0.73 |
| Beta | -0.12 | Avg Volume | 600.70K | Volume | 10.89K |
| Target Price | — | Recom | None | Prev Close | $1.07 |
| Price | $1.04 | Change | -2.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.04
Latest analyst target
3. DCF / Fair value
$-3.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.04
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-10 | reit | Benchmark | Speculative Buy → Speculative Buy | $5 |
| 2024-06-11 | reit | Benchmark | Speculative Buy → Speculative Buy | $5 |
| 2023-12-04 | reit | Benchmark | Speculative Buy → Speculative Buy | $5 |
| 2023-07-21 | init | Benchmark | — → Speculative Buy | $5 |
- Cancer cell therapy company hits back at claims about its first human trial - Stock Titan Wed, 28 Jan 2026 08
- Why Did CytoMed Therapeutics Stock Jump 19% Today? - Stocktwits ue, 14 Oct 2025 07
- CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - Yahoo Finance Fri, 06 Feb 2026 08
- CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress - Sahm Wed, 28 Jan 2026 08
- CytoMed Therapeutics (NASDAQ: GDTC) Chairman Now Owns 21.95%, 2,388,246 Shares - Stock Titan Wed, 22 Oct 2025 07
- 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga Fri, 13 Feb 2026 21
- CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - simplywall.st Fri, 06 Feb 2026 08
- CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital - ChartMill ue, 13 Jan 2026 08
- CytoMed Therapeutics (NASDAQ: GDTC) to run first-in-human Malaysia trial of donor-derived γδ T cells - Stock Titan Mon, 08 Dec 2025 08
- GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView ue, 23 Jan 2024 08
- Biotech seeks investor views on share-based access to cell therapy - Stock Titan ue, 13 Jan 2026 08
- Second acquisition in a year — CytoMed bids for TC BioPharm assets to bolster allogeneic cell pipeline - Stock Titan ue, 14 Oct 2025 07
- Royal Caribbean (NYSE: RCL) launches unsecured notes sale to finance Celebrity Xcel - Stock Titan ue, 18 Nov 2025 08
- GDTC - CytoMed Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan Fri, 14 Apr 2023 00
- CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 1% – Still a Buy? - Defense World Fri, 20 Feb 2026 10
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -67.01K | -4.44K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.17 | 0.17 | 0.00 |
| NormalizedEBITDA | -2.46M | -3.31M | -2.59M | -1.59M |
| TotalUnusualItems | 297.55K | -394.16K | -26.14K | -9.48K |
| TotalUnusualItemsExcludingGoodwill | 297.55K | -394.16K | -26.14K | -9.48K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -2.52M | -4.13M | -3.13M | -2.05M |
| ReconciledDepreciation | 335.36K | 381.15K | 392.87K | 329.88K |
| ReconciledCostOfRevenue | 17.12K | 0.00 | 0.00 | |
| EBITDA | -2.17M | -3.70M | -2.61M | -1.60M |
| EBIT | -2.50M | -4.08M | -3.00M | -1.93M |
| NetInterestIncome | 297.36K | 234.44K | -123.08K | -114.33K |
| InterestExpense | 20.31K | 51.28K | 125.17K | 117.70K |
| InterestIncome | 317.67K | 285.72K | 2.10K | 3.37K |
| NormalizedIncome | -2.81M | -3.81M | -3.11M | -2.04M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -2.52M | -4.13M | -3.13M | -2.05M |
| TotalExpenses | 3.20M | 3.84M | 1.86M | 1.73M |
| RentExpenseSupplemental | 3.21K | 1.70K | 2.20K | 2.00K |
| DilutedAverageShares | 10.63M | 10.94M | 10.94M | |
| BasicAverageShares | 10.63M | 10.94M | 10.94M | |
| DilutedEPS | -0.39 | -0.29 | -0.19 | |
| BasicEPS | -0.39 | -0.29 | -0.19 | |
| DilutedNIAvailtoComStockholders | -2.52M | -4.13M | -3.13M | -2.05M |
| NetIncomeCommonStockholders | -2.52M | -4.13M | -3.13M | -2.05M |
| NetIncome | -2.52M | -4.13M | -3.13M | -2.05M |
| MinorityInterests | 5.16K | 274.00 | 243.00 | 253.00 |
| NetIncomeIncludingNoncontrollingInterests | -2.52M | -4.13M | -3.13M | -2.05M |
| NetIncomeContinuousOperations | -2.52M | -4.13M | -3.13M | -2.05M |
| TaxProvision | 0.00 | 653.00 | 1.64K | 0.00 |
| PretaxIncome | -2.52M | -4.13M | -3.13M | -2.05M |
| OtherIncomeExpense | 311.31K | -524.11K | -1.15M | -209.39K |
| OtherNonOperatingIncomeExpenses | -98.75K | -1.09M | 12.67K | |
| SpecialIncomeCharges | 0.00 | 0.00 | 280.00 | 0.00 |
| GainOnSaleOfPPE | 0.00 | 0.00 | 280.00 | 0.00 |
| EarningsFromEquityInterest | 13.77K | -31.20K | -33.55K | -212.58K |
| GainOnSaleOfSecurity | 297.55K | -394.16K | -26.42K | -9.48K |
| NetNonOperatingInterestIncomeExpense | 297.36K | 234.44K | -123.08K | -114.33K |
| InterestExpenseNonOperating | 20.31K | 51.28K | 125.17K | 117.70K |
| InterestIncomeNonOperating | 317.67K | 285.72K | 2.10K | 3.37K |
| OperatingIncome | -3.13M | -3.84M | -1.86M | -1.73M |
| OperatingExpense | 3.18M | 3.84M | 1.86M | 1.73M |
| OtherOperatingExpenses | -123.11K | 858.30K | -182.10K | 240.93K |
| OtherTaxes | 8.41K | 6.66K | 7.04K | 4.08K |
| DepreciationAmortizationDepletionIncomeStatement | 122.40K | 104.05K | 111.75K | 101.23K |
| DepreciationAndAmortizationInIncomeStatement | 122.40K | 104.05K | 111.75K | 101.23K |
| Amortization | 12.56K | 2.19K | 2.50K | 2.51K |
| AmortizationOfIntangiblesIncomeStatement | 12.56K | 2.19K | 2.50K | 2.51K |
| DepreciationIncomeStatement | 109.84K | 101.87K | 109.25K | 98.72K |
| ResearchAndDevelopment | 1.91M | 1.59M | 1.52M | 1.09M |
| SellingGeneralAndAdministration | 1.27M | 1.28M | 397.11K | 291.32K |
| SellingAndMarketingExpense | 23.78K | 33.31K | 0.00 | 2.48K |
| GeneralAndAdministrativeExpense | 1.24M | 1.25M | 397.11K | 288.83K |
| OtherGandA | 525.00K | 512.19K | 184.25K | 118.04K |
| InsuranceAndClaims | 94.37K | 282.80K | 0.00 | 0.00 |
| RentAndLandingFees | 3.21K | 1.70K | 2.20K | 2.00K |
| SalariesAndWages | 619.33K | 454.14K | 210.66K | 168.80K |
| GrossProfit | 52.38K | 0.00 | 0.00 | |
| CostOfRevenue | 17.12K | 0.00 | 0.00 | |
| TotalRevenue | 69.50K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 69.50K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 11.54M | 11.53M | 10.94M | 10.94M |
| ShareIssued | 11.54M | 11.53M | 10.94M | 10.94M |
| NetDebt | 2.63M | 722.80K | ||
| TotalDebt | 463.25K | 448.02K | 4.22M | 3.26M |
| TangibleBookValue | 8.87M | 11.23M | 568.17K | 2.56M |
| InvestedCapital | 9.40M | 11.69M | 4.79M | 5.83M |
| WorkingCapital | 5.39M | 9.38M | -1.67M | 345.26K |
| NetTangibleAssets | 8.87M | 11.23M | 568.17K | 2.56M |
| CapitalLeaseObligations | 31.29K | 6.32K | 14.42K | 23.13K |
| CommonStockEquity | 8.97M | 11.25M | 586.98K | 2.59M |
| TotalCapitalization | 9.36M | 11.65M | 1.06M | 3.13M |
| TotalEquityGrossMinorityInterest | 9.04M | 11.24M | 586.30K | 2.59M |
| MinorityInterest | 77.75K | -956.00 | -682.00 | -439.00 |
| StockholdersEquity | 8.97M | 11.25M | 586.98K | 2.59M |
| OtherEquityInterest | 73.93K | 1.14M | ||
| GainsLossesNotAffectingRetainedEarnings | 20.23K | -217.40K | -127.48K | -30.98K |
| OtherEquityAdjustments | 73.98K | |||
| ForeignCurrencyTranslationAdjustments | -53.76K | -217.40K | -127.48K | -30.98K |
| RetainedEarnings | -14.85M | -12.33M | -8.20M | -5.07M |
| CapitalStock | 23.79M | 23.72M | 8.91M | 6.55M |
| CommonStock | 23.79M | 23.72M | 8.91M | 6.55M |
| TotalLiabilitiesNetMinorityInterest | 1.02M | 1.12M | 4.64M | 3.49M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 417.34K | 407.77K | 475.54K | 554.44K |
| LongTermDebtAndCapitalLeaseObligation | 417.34K | 407.77K | 475.54K | 554.44K |
| LongTermCapitalLeaseObligation | 23.03K | 0.00 | 6.71K | 15.32K |
| LongTermDebt | 394.31K | 407.77K | 468.83K | 539.12K |
| CurrentLiabilities | 606.62K | 716.94K | 4.17M | 2.94M |
| OtherCurrentLiabilities | 11.95K | 146.61K | ||
| CurrentDeferredLiabilities | 109.15K | 8.40K | 9.10K | 21.97K |
| CurrentDeferredRevenue | 109.15K | 8.40K | 9.10K | 21.97K |
| CurrentDebtAndCapitalLeaseObligation | 45.91K | 40.25K | 3.74M | 2.70M |
| CurrentCapitalLeaseObligation | 8.26K | 6.32K | 7.71K | 7.81K |
| CurrentDebt | 37.65K | 33.93K | 3.74M | 2.70M |
| OtherCurrentBorrowings | 37.65K | 33.93K | 3.74M | 2.70M |
| PayablesAndAccruedExpenses | 439.62K | 521.68K | 412.39K | 210.25K |
| CurrentAccruedExpenses | 363.69K | 446.63K | 235.91K | 144.70K |
| Payables | 75.92K | 75.05K | 176.48K | 65.55K |
| OtherPayable | 37.29K | 50.43K | 159.00K | 18.04K |
| DuetoRelatedPartiesCurrent | 0.00 | 1.26K | 1.26K | |
| TotalTaxPayable | 0.00 | 1.60K | 0.00 | |
| AccountsPayable | 38.63K | 24.62K | 14.63K | 46.25K |
| TotalAssets | 10.07M | 12.37M | 5.23M | 6.08M |
| TotalNonCurrentAssets | 4.07M | 2.27M | 2.73M | 2.80M |
| NonCurrentAccountsReceivable | 500.00K | |||
| InvestmentsAndAdvances | 220.95K | 195.07K | 239.42K | 272.97K |
| LongTermEquityInvestment | 220.95K | 195.07K | 239.42K | 272.97K |
| InvestmentsinAssociatesatCost | 220.95K | 195.07K | 239.42K | 272.97K |
| GoodwillAndOtherIntangibleAssets | 93.05K | 12.41K | 18.81K | 32.02K |
| OtherIntangibleAssets | 92.69K | 12.06K | 18.45K | 31.67K |
| Goodwill | 355.00 | 355.00 | 355.00 | 355.00 |
| NetPPE | 3.25M | 2.06M | 2.47M | 2.50M |
| AccumulatedDepreciation | -1.77M | -1.36M | -1.05M | -737.67K |
| GrossPPE | 5.02M | 3.43M | 3.53M | 3.23M |
| OtherProperties | 1.99M | 1.67M | 1.70M | 1.35M |
| MachineryFurnitureEquipment | 447.80K | 330.20K | 336.00K | 326.99K |
| BuildingsAndImprovements | 1.99M | 1.06M | 1.10M | 1.13M |
| LandAndImprovements | 588.04K | 372.21K | 394.89K | 419.51K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 6.00M | 10.10M | 2.49M | 3.28M |
| PrepaidAssets | 909.13K | 896.82K | 856.56K | 763.68K |
| Receivables | 121.21K | 204.75K | 57.58K | 5.29K |
| OtherReceivables | 63.12K | 13.31K | 57.58K | 4.03K |
| DuefromRelatedPartiesCurrent | 0.00 | 1.26K | ||
| TaxesReceivable | 2.89K | 4.71K | ||
| AccruedInterestReceivable | 36.41K | 186.73K | ||
| AccountsReceivable | 18.78K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 4.97M | 9.00M | 1.58M | 2.51M |
| CashAndCashEquivalents | 4.97M | 9.00M | 1.58M | 2.51M |
| CashFinancial | 4.97M | 9.00M | 1.58M | 2.51M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.20M | -3.59M | -1.87M | -2.30M |
| RepaymentOfDebt | -44.58K | -340.43K | -428.76K | -58.91K |
| IssuanceOfDebt | 0.00 | 0.00 | 300.00K | 350.00K |
| IssuanceOfCapitalStock | 0.00 | 11.31M | 1.22M | 2.00M |
| CapitalExpenditure | -1.49M | -58.30K | -473.80K | -582.35K |
| EndCashPosition | 4.70M | 6.22M | 1.58M | 2.51M |
| BeginningCashPosition | 6.22M | 1.58M | 2.51M | 885.27K |
| EffectOfExchangeRateChanges | 121.14K | -13.41K | -30.05K | -9.25K |
| ChangesInCash | -1.65M | 4.66M | -903.00K | 1.64M |
| FinancingCashFlow | -64.89K | 10.92M | 968.72K | 4.17M |
| CashFlowFromContinuingFinancingActivities | -64.89K | 10.92M | 968.72K | 4.17M |
| NetOtherFinancingCharges | 2.00M | |||
| InterestPaidCFF | -20.31K | -46.71K | -125.17K | -117.70K |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 0.00 | 11.31M | 1.22M | 2.00M |
| CommonStockIssuance | 0.00 | 11.31M | 1.22M | 2.00M |
| NetIssuancePaymentsOfDebt | -44.58K | -340.43K | -128.76K | 291.09K |
| NetShortTermDebtIssuance | -300.00K | -50.00K | 350.00K | |
| ShortTermDebtPayments | -300.00K | -350.00K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 300.00K | 350.00K | |
| NetLongTermDebtIssuance | -44.58K | -340.43K | -128.76K | -58.91K |
| LongTermDebtPayments | -44.58K | -340.43K | -428.76K | -58.91K |
| LongTermDebtIssuance | 0.00 | 0.00 | 300.00K | 0.00 |
| InvestingCashFlow | 1.13M | -2.73M | -473.31K | -823.67K |
| CashFlowFromContinuingInvestingActivities | 1.13M | -2.73M | -473.31K | -823.67K |
| NetOtherInvestingChanges | -342.15K | |||
| InterestReceivedCFI | 465.57K | 98.37K | 0.00 | |
| NetInvestmentPurchaseAndSale | 2.50M | -2.77M | 0.00 | 0.00 |
| SaleOfInvestment | 2.50M | |||
| PurchaseOfInvestment | -2.77M | 0.00 | 0.00 | |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -241.31K | |
| PurchaseOfBusiness | 0.00 | 0.00 | -241.31K | |
| NetIntangiblesPurchaseAndSale | -94.21K | 0.00 | 0.00 | 0.00 |
| PurchaseOfIntangibles | -94.21K | 0.00 | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -1.40M | -58.30K | -473.31K | -582.35K |
| SaleOfPPE | 0.00 | 0.00 | 490.00 | 0.00 |
| PurchaseOfPPE | -1.40M | -58.30K | -473.80K | -582.35K |
| OperatingCashFlow | -2.71M | -3.53M | -1.40M | -1.71M |
| CashFlowFromContinuingOperatingActivities | -2.71M | -3.53M | -1.40M | -1.71M |
| TaxesRefundPaid | 0.00 | -2.19K | 0.00 | 0.00 |
| InterestReceivedCFO | 2.42K | 623.00 | 2.10K | 3.37K |
| ChangeInWorkingCapital | -60.41K | 104.92K | 109.90K | -369.25K |
| ChangeInOtherWorkingCapital | 102.29K | 1.95K | -9.99K | |
| ChangeInPayablesAndAccruedExpense | -83.60K | 108.22K | 265.06K | 63.87K |
| ChangeInPayable | -83.60K | 108.22K | 265.06K | 63.87K |
| ChangeInReceivables | -79.09K | -5.26K | -145.17K | -433.12K |
| OtherNonCashItems | -297.36K | -234.44K | 123.08K | 114.33K |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 98.75K | 1.09M | -12.67K |
| AssetImpairmentCharge | 0.00 | 0.00 | 1.37K | 0.00 |
| DepreciationAmortizationDepletion | 335.36K | 381.15K | 392.87K | 329.88K |
| DepreciationAndAmortization | 335.36K | 381.15K | 392.87K | 329.88K |
| AmortizationCashFlow | 13.20K | 6.40K | 13.20K | 13.21K |
| AmortizationOfIntangibles | 13.20K | 6.40K | 13.20K | 13.21K |
| Depreciation | 322.16K | 374.75K | 379.67K | 316.67K |
| OperatingGainsLosses | -168.09K | 252.51K | 11.61K | 273.26K |
| EarningsLossesFromEquityInvestments | -13.77K | 31.20K | 33.55K | 212.58K |
| GainLossOnInvestmentSecurities | -138.29K | 223.84K | ||
| NetForeignCurrencyExchangeGainLoss | -16.03K | -2.53K | -21.66K | 60.68K |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | -280.00 | 0.00 |
| NetIncomeFromContinuingOperations | -2.52M | -4.13M | -3.13M | -2.05M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for GDTC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|